Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition

Konstantinos K. Tsilidis, Naomi E. Allen, Timothy J. Key, Miguel A. Sanjoaquin, Kjersti Bakken, Franco Berrino, Agnès Fournier, Eiliv Lund, Kim Overvad, Anja Olsen, Anne Tjønneland, Graham Byrnes, Veronique Chajes, Sabina Rinaldi, Marie Christine Boutron-Ruault, Francoise Clavel-Chapelon, Jenny Chang-Claude, Rudolf Kaaks, Manuela Bergmann, Heiner BoeingYvoni Koumantaki, Domenico Palli, Valeria Pala, Salvatore Panico, Rosario Tumino, Paolo Vineis, H. Bas Bueno-De-Mesquita, Carla H. Van Gils, Petra H M Peeters, Laudina Rodríguez, Carlos A. González, María José Sánchez, Maria Dolores Chirlaque, Aurelio Barricarte, Miren Dorronsoro, Kay Tee Khaw, Sheila A. Rodwell, Teresa Norat, Dora Romaguera, Elio Riboli

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Menopausal hormone therapy (HT) may influence colorectal cancer risk. A total of 136,275 postmenopausal women from the European Prospective Investigation into Cancer and Nutrition were followed for an average of 9 years, during which time 1,186 colorectal cancers were diagnosed. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox proportional hazards models stratified by center and age, and adjusted for body mass index, smoking, diabetes, physical activity and alcohol consumption. Compared to never use of HT at study enrolment, current use of estrogen-only (HR, 1.02; 95% CI, 0.79-1.31) or estrogen plus progestin (HR, 0.94; 95% CI, 0.77-1.14) was not significantly associated with the risk of colorectal cancer, and these associations did not vary by recency, duration, route of administration, regimen or specific constituent of HT. Our results show no significant association of estrogen-only or estrogen plus progestin therapy with colorectal cancer risk.

Original languageEnglish
Pages (from-to)1881-1889
Number of pages9
JournalInternational Journal of Cancer
Volume128
Issue number8
DOIs
Publication statusPublished - Apr 15 2011

Fingerprint

Colorectal Neoplasms
Estrogens
Hormones
Progestins
Confidence Intervals
Neoplasms
Therapeutics
Proportional Hazards Models
Alcohol Drinking
Body Mass Index
Smoking
Exercise

Keywords

  • cohort study
  • colorectal cancer
  • hormone replacement therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tsilidis, K. K., Allen, N. E., Key, T. J., Sanjoaquin, M. A., Bakken, K., Berrino, F., ... Riboli, E. (2011). Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 128(8), 1881-1889. https://doi.org/10.1002/ijc.25504

Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. / Tsilidis, Konstantinos K.; Allen, Naomi E.; Key, Timothy J.; Sanjoaquin, Miguel A.; Bakken, Kjersti; Berrino, Franco; Fournier, Agnès; Lund, Eiliv; Overvad, Kim; Olsen, Anja; Tjønneland, Anne; Byrnes, Graham; Chajes, Veronique; Rinaldi, Sabina; Boutron-Ruault, Marie Christine; Clavel-Chapelon, Francoise; Chang-Claude, Jenny; Kaaks, Rudolf; Bergmann, Manuela; Boeing, Heiner; Koumantaki, Yvoni; Palli, Domenico; Pala, Valeria; Panico, Salvatore; Tumino, Rosario; Vineis, Paolo; Bas Bueno-De-Mesquita, H.; Van Gils, Carla H.; Peeters, Petra H M; Rodríguez, Laudina; González, Carlos A.; Sánchez, María José; Chirlaque, Maria Dolores; Barricarte, Aurelio; Dorronsoro, Miren; Khaw, Kay Tee; Rodwell, Sheila A.; Norat, Teresa; Romaguera, Dora; Riboli, Elio.

In: International Journal of Cancer, Vol. 128, No. 8, 15.04.2011, p. 1881-1889.

Research output: Contribution to journalArticle

Tsilidis, KK, Allen, NE, Key, TJ, Sanjoaquin, MA, Bakken, K, Berrino, F, Fournier, A, Lund, E, Overvad, K, Olsen, A, Tjønneland, A, Byrnes, G, Chajes, V, Rinaldi, S, Boutron-Ruault, MC, Clavel-Chapelon, F, Chang-Claude, J, Kaaks, R, Bergmann, M, Boeing, H, Koumantaki, Y, Palli, D, Pala, V, Panico, S, Tumino, R, Vineis, P, Bas Bueno-De-Mesquita, H, Van Gils, CH, Peeters, PHM, Rodríguez, L, González, CA, Sánchez, MJ, Chirlaque, MD, Barricarte, A, Dorronsoro, M, Khaw, KT, Rodwell, SA, Norat, T, Romaguera, D & Riboli, E 2011, 'Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition', International Journal of Cancer, vol. 128, no. 8, pp. 1881-1889. https://doi.org/10.1002/ijc.25504
Tsilidis, Konstantinos K. ; Allen, Naomi E. ; Key, Timothy J. ; Sanjoaquin, Miguel A. ; Bakken, Kjersti ; Berrino, Franco ; Fournier, Agnès ; Lund, Eiliv ; Overvad, Kim ; Olsen, Anja ; Tjønneland, Anne ; Byrnes, Graham ; Chajes, Veronique ; Rinaldi, Sabina ; Boutron-Ruault, Marie Christine ; Clavel-Chapelon, Francoise ; Chang-Claude, Jenny ; Kaaks, Rudolf ; Bergmann, Manuela ; Boeing, Heiner ; Koumantaki, Yvoni ; Palli, Domenico ; Pala, Valeria ; Panico, Salvatore ; Tumino, Rosario ; Vineis, Paolo ; Bas Bueno-De-Mesquita, H. ; Van Gils, Carla H. ; Peeters, Petra H M ; Rodríguez, Laudina ; González, Carlos A. ; Sánchez, María José ; Chirlaque, Maria Dolores ; Barricarte, Aurelio ; Dorronsoro, Miren ; Khaw, Kay Tee ; Rodwell, Sheila A. ; Norat, Teresa ; Romaguera, Dora ; Riboli, Elio. / Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. In: International Journal of Cancer. 2011 ; Vol. 128, No. 8. pp. 1881-1889.
@article{115a2cac264348eb89ef6a169e37ceb7,
title = "Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition",
abstract = "Menopausal hormone therapy (HT) may influence colorectal cancer risk. A total of 136,275 postmenopausal women from the European Prospective Investigation into Cancer and Nutrition were followed for an average of 9 years, during which time 1,186 colorectal cancers were diagnosed. Hazard ratios (HR) and 95{\%} confidence intervals (CI) were estimated using Cox proportional hazards models stratified by center and age, and adjusted for body mass index, smoking, diabetes, physical activity and alcohol consumption. Compared to never use of HT at study enrolment, current use of estrogen-only (HR, 1.02; 95{\%} CI, 0.79-1.31) or estrogen plus progestin (HR, 0.94; 95{\%} CI, 0.77-1.14) was not significantly associated with the risk of colorectal cancer, and these associations did not vary by recency, duration, route of administration, regimen or specific constituent of HT. Our results show no significant association of estrogen-only or estrogen plus progestin therapy with colorectal cancer risk.",
keywords = "cohort study, colorectal cancer, hormone replacement therapy",
author = "Tsilidis, {Konstantinos K.} and Allen, {Naomi E.} and Key, {Timothy J.} and Sanjoaquin, {Miguel A.} and Kjersti Bakken and Franco Berrino and Agn{\`e}s Fournier and Eiliv Lund and Kim Overvad and Anja Olsen and Anne Tj{\o}nneland and Graham Byrnes and Veronique Chajes and Sabina Rinaldi and Boutron-Ruault, {Marie Christine} and Francoise Clavel-Chapelon and Jenny Chang-Claude and Rudolf Kaaks and Manuela Bergmann and Heiner Boeing and Yvoni Koumantaki and Domenico Palli and Valeria Pala and Salvatore Panico and Rosario Tumino and Paolo Vineis and {Bas Bueno-De-Mesquita}, H. and {Van Gils}, {Carla H.} and Peeters, {Petra H M} and Laudina Rodr{\'i}guez and Gonz{\'a}lez, {Carlos A.} and S{\'a}nchez, {Mar{\'i}a Jos{\'e}} and Chirlaque, {Maria Dolores} and Aurelio Barricarte and Miren Dorronsoro and Khaw, {Kay Tee} and Rodwell, {Sheila A.} and Teresa Norat and Dora Romaguera and Elio Riboli",
year = "2011",
month = "4",
day = "15",
doi = "10.1002/ijc.25504",
language = "English",
volume = "128",
pages = "1881--1889",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition

AU - Tsilidis, Konstantinos K.

AU - Allen, Naomi E.

AU - Key, Timothy J.

AU - Sanjoaquin, Miguel A.

AU - Bakken, Kjersti

AU - Berrino, Franco

AU - Fournier, Agnès

AU - Lund, Eiliv

AU - Overvad, Kim

AU - Olsen, Anja

AU - Tjønneland, Anne

AU - Byrnes, Graham

AU - Chajes, Veronique

AU - Rinaldi, Sabina

AU - Boutron-Ruault, Marie Christine

AU - Clavel-Chapelon, Francoise

AU - Chang-Claude, Jenny

AU - Kaaks, Rudolf

AU - Bergmann, Manuela

AU - Boeing, Heiner

AU - Koumantaki, Yvoni

AU - Palli, Domenico

AU - Pala, Valeria

AU - Panico, Salvatore

AU - Tumino, Rosario

AU - Vineis, Paolo

AU - Bas Bueno-De-Mesquita, H.

AU - Van Gils, Carla H.

AU - Peeters, Petra H M

AU - Rodríguez, Laudina

AU - González, Carlos A.

AU - Sánchez, María José

AU - Chirlaque, Maria Dolores

AU - Barricarte, Aurelio

AU - Dorronsoro, Miren

AU - Khaw, Kay Tee

AU - Rodwell, Sheila A.

AU - Norat, Teresa

AU - Romaguera, Dora

AU - Riboli, Elio

PY - 2011/4/15

Y1 - 2011/4/15

N2 - Menopausal hormone therapy (HT) may influence colorectal cancer risk. A total of 136,275 postmenopausal women from the European Prospective Investigation into Cancer and Nutrition were followed for an average of 9 years, during which time 1,186 colorectal cancers were diagnosed. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox proportional hazards models stratified by center and age, and adjusted for body mass index, smoking, diabetes, physical activity and alcohol consumption. Compared to never use of HT at study enrolment, current use of estrogen-only (HR, 1.02; 95% CI, 0.79-1.31) or estrogen plus progestin (HR, 0.94; 95% CI, 0.77-1.14) was not significantly associated with the risk of colorectal cancer, and these associations did not vary by recency, duration, route of administration, regimen or specific constituent of HT. Our results show no significant association of estrogen-only or estrogen plus progestin therapy with colorectal cancer risk.

AB - Menopausal hormone therapy (HT) may influence colorectal cancer risk. A total of 136,275 postmenopausal women from the European Prospective Investigation into Cancer and Nutrition were followed for an average of 9 years, during which time 1,186 colorectal cancers were diagnosed. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox proportional hazards models stratified by center and age, and adjusted for body mass index, smoking, diabetes, physical activity and alcohol consumption. Compared to never use of HT at study enrolment, current use of estrogen-only (HR, 1.02; 95% CI, 0.79-1.31) or estrogen plus progestin (HR, 0.94; 95% CI, 0.77-1.14) was not significantly associated with the risk of colorectal cancer, and these associations did not vary by recency, duration, route of administration, regimen or specific constituent of HT. Our results show no significant association of estrogen-only or estrogen plus progestin therapy with colorectal cancer risk.

KW - cohort study

KW - colorectal cancer

KW - hormone replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=79951994752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951994752&partnerID=8YFLogxK

U2 - 10.1002/ijc.25504

DO - 10.1002/ijc.25504

M3 - Article

C2 - 20533550

AN - SCOPUS:79951994752

VL - 128

SP - 1881

EP - 1889

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 8

ER -